Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Terminated × Trastuzumab × Clear all

Phase

Phase 2 48 Phase 1/2 19 Phase 1 11 Phase 3 8 Phase 4 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Not yet recruiting 3 Completed 3 Active not recruiting 3 Unknown 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Gemcitabine 8 Carboplatin 7 Paclitaxel 6 Fluorouracil 6 Cyclophosphamide 6 Cisplatin 6 Docetaxel 5 Capecitabine 5 Stem Cell Transplantation 3 Radiotherapy 3 Pemetrexed 3 Melphalan 3 Leucovorin 3 Etoposide 3 Bevacizumab 3 umbralisib 2 ublituximab 2 fludarabine 2 Vinorelbine 2 Transplantation, Homologous 2 Surveys and Questionnaires 2 S 1 (combination) 2 Oxaliplatin 2 Nivolumab 2 Mitomycin 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡